JPRN-UMIN000015984已完成2 期
Efficacy of crizotinib in alectinib-refractory patients with NSCLC harboring EML4-ALK; phaseII trial (OLCSG1405) - Efficacy of crizotinib in alectinib-refractory patients; phase2 trial (OLCSG1405)
Okayama Lung Cancer Study Group0 个研究点目标入组 9 人开始时间: 2014年12月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with symptomatic brain metastases. Pregnant women, nursing mothers, the women who may be pregnant or have the will to get pregnant, and the men who hope for fertility with pregnancy. The patients with a history of hypersensitivity to crizotinib.
研究者
相似试验
已完成
1 期
A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastomaJPRN-UMIN000028075St. Marianna University School of Medicine Hospital National Center for Child Health and Development Nagoya Medical Center Kyushu University Hospital23
已完成
2 期
A-LiquidJPRN-jRCT2080225060Department of Thoracic Oncology, National Cancer Center Hospital East25
招募中
不适用
A phase IB study of crizotinib in pediatric malignancieschildren, cancer, pediatric malignancies, ALK positive tumors, ROS1 positive tumors, MET positive tumorskinderen, kanker, pediatrische maligniteiten, tumoren positief voor ALK, ROS1, MET afwijkingenNL-OMON24969niversity Medical Center Erasmus Medical Center Rotterdam The Netherlands82
已完成
不适用
Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trialsnon-small cell lung cancerJPRN-UMIN000036861Showa University School of Medicine, Department of Medicine, Division of Respiratory Medicine and Allergology,785
已完成
1 期
Phase I study of Erlotinib and Crizotinib after ALK inhibitor failure in ALK positive advanced Non-Small Cell Lung CancerALK inhibitor failure in ALK positive advanced Non-Small Cell Lung CancerJPRN-UMIN000010090Medical thoracic oncology, Cancer institute hospital, Japanese Foundation For Cancer Reseach30